Initiate Phase 2 SURPASS-2 trial of ADP-A2M4CD8 in esophageal and EGJ cancers
Delivered after the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 25 Feb 2021
- Due
- 30 Jun 2021
- Delivered
- Q3 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Initiating Phase 2 trial (SURPASS-2) with ADP-A2M4CD8 in esophageal and esophagogastric junction cancers in 1H 2021”
What we found
Evidence strength A What the grades mean
The company's August 2021 10-Q still planned the Phase 2 start for Q3 2021, and the November 2021 10-Q said it was initiated during Q3 2021, after the 1H 2021 deadline.
-
A Adaptimmune Therapeutics plc 10-Q filed 2021-08-09
“we are planning to initiate a Phase 2 clinical trial with ADP-A2M4CD8 in esophageal and esophagogastric junction (“EGJ”) cancers in the third quarter of 2021.” ✓ confirmed on the page
-
A Adaptimmune Therapeutics plc 10-Q filed 2021-11-04
“was initiated during the third quarter of 2021” ✓ confirmed on the page
Checked 26 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Deliverable
- SURPASS-2 Phase 2 trial initiation
- Where
- North America and the EU
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Adaptimmune Therapeutics plc? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-ADAPY-024583 · Corrections policy